TY - JOUR
T1 - Early treatment with erythromycin of Campylobacter jejuni-associated dysentery in children
AU - Salazar-Lindo, Eduardo
AU - Sack, R. Bradley
AU - Chea-Woo, Elsa
AU - Kay, Bradford A.
AU - Piscoya, Zolia A.
AU - Leon-Barua, Raul
AU - Yi, August
N1 - Funding Information:
Several authors have recommended erythromycin as the drug of choice in treating symptomatic Campylobacter jejuni infections, based on studies of in vitro susceptibility of the organism to antimicrobial agents ~3 and on uncontrolled clinical observations. 47 Recently published con- Presented in part at the 21st U.S.-Japan Cholera Conference, October 21-23, 1985. Supported by grants from Abbott Laboratories and Nestec Ltd., Vevey, Switzerland. Submitted for publication Nov. 18, 1985; accepted March 4, 1986. Reprint requests: R. Bradley Sack, M.D., The Johns Hopkins University School of Public Health, Department of International Health, Division of Geographic Medicine, 615 N. Wolfe St., Baltimore, MD 21205.
PY - 1986/8
Y1 - 1986/8
N2 - To evaluate the efficacy of early treatment with erythromycin on the duration of fecal excretion and of diarrhea associated with Campylobacter jejuni, 170 patients, age 3 to 60 months, were randomly assigned in a double-blind fashion to receive either erythromycin ethyl succinate or placebo immediately after being seen at Cayetano Heredia Hospital because of acute dysentery. The groups' pretreatment characteristics were comparable. Of the 30 patients with stools positive for C. jejuni, 12 were in the placebo group and 16 in the treatment group. After 2 days of treatment, none of the patients in the placebo group and 36% of those in the erythromycin group had normal stools (P<0.05). After 5 days of treatment, 50% of the patients in the placebo group and 93% of those in the erythromycin group had normal stools (P<0.02). Fecal excretion of the organism continued significantly longer in the placebo group (P<0.01). There were no treatment failures in the treatment group compared with five (42%) in the placebo group (P<0.01). Thus, early administration of erythromycin significantly reduced the duration of both diarrhea and fecal excretion of the organism in infants and children with acute dysentery associated with C. jejuni.
AB - To evaluate the efficacy of early treatment with erythromycin on the duration of fecal excretion and of diarrhea associated with Campylobacter jejuni, 170 patients, age 3 to 60 months, were randomly assigned in a double-blind fashion to receive either erythromycin ethyl succinate or placebo immediately after being seen at Cayetano Heredia Hospital because of acute dysentery. The groups' pretreatment characteristics were comparable. Of the 30 patients with stools positive for C. jejuni, 12 were in the placebo group and 16 in the treatment group. After 2 days of treatment, none of the patients in the placebo group and 36% of those in the erythromycin group had normal stools (P<0.05). After 5 days of treatment, 50% of the patients in the placebo group and 93% of those in the erythromycin group had normal stools (P<0.02). Fecal excretion of the organism continued significantly longer in the placebo group (P<0.01). There were no treatment failures in the treatment group compared with five (42%) in the placebo group (P<0.01). Thus, early administration of erythromycin significantly reduced the duration of both diarrhea and fecal excretion of the organism in infants and children with acute dysentery associated with C. jejuni.
UR - http://www.scopus.com/inward/record.url?scp=0022508390&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022508390&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(86)80404-8
DO - 10.1016/S0022-3476(86)80404-8
M3 - Article
C2 - 3488385
AN - SCOPUS:0022508390
SN - 0022-3476
VL - 109
SP - 355
EP - 360
JO - The Journal of pediatrics
JF - The Journal of pediatrics
IS - 2
ER -